Recent News

• 04.08.2025 - Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
• 04.07.2025 - Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress
• 04.02.2025 - Opus Genetics to Participate in Upcoming Investor Conference in April
• 03.31.2025 - Opus Genetics Announces Financial Results for Full Year 2024

Recent Filings

• 04.08.2025 - S-3/A Registration statement under Securities Act of 1933
• 04.07.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.04.2025 - 8-K Current report
• 04.04.2025 - PRRN14A Non-management revised preliminary proxy soliciting materials, contested and otherwise
• 04.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.02.2025 - DEFC14A Definitive proxy statement, contested solicitations
• 04.02.2025 - DFAN14A Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
• 03.31.2025 - PRER14A Preliminary Proxy Soliciting materials
• 03.31.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]